The Reliability-Quality Relationship for Quality Systems and Quality Risk Management

References

1. 1.↵
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline, Pharmaceutical Quality System Q10, Current Step 4, version dated June 2008.
2. 2.
   ICH. Harmonised Tripartite Guideline, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7, Current Step 4, version dated 10 November 2000.
3. 3.
   ICH. Harmonised Tripartite Guideline, Pharmaceutical Development Q8(R2), ICH Current Step 4, version dated August 2009. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html, accessed July 20; 2011.
4. 4.↵
   ICH. Harmonised Tripartite Guideline, Quality Risk Management Q9, Final Step 4 Document, 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf, accessed September 29, 2011.
5. 5.↵
   ICH. Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities), Draft Consensus Guideline Current Step 2, dated 19 May 2011, http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html, accessed July 20, 2011.
6. 6.↵
   FDA. Process Validation: General Principles and Practices (CDER, Center for Biologics Evaluation and Research, and CVM), Guidance for Industry, January 2011, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070336.pdf, accessed April 5, 2012.
7. 7.↵
   1. Modarres M.,
   2. Kaminskiy M.,
   3. Krivtsov V.

   Reliability Engineering and Risk Analysis. Marcel Dekker, Inc.: New York, 1999.
8. 8.↵
   1. Modarres M.

   What Every Engineer Should Know About Reliability and Risk Analysis; Marcel Dekker, Inc.: New York, 1993.
9. 9.↵
   1. Ayyub B. M.

   Risk Analysis in Engineering and Economics; Chapman Hall/CRC: Boca Raton, FL, 2003.
10. 10.↵
    1. Todinov M. T.

    Reliability analysis based on the losses from failures. Risk Anal. 2006, 26 (2), 311–335.

    OpenUrlPubMed
11. 11.↵
    1. Podofillini L.,
    2. Dang V.,
    3. Zio E.,
    4. Baraldi P.,
    5. Librizzi M.

    Using expert models in human reliability analysis—a dependence assessment method based on fuzzy logic, Risk Anal. 2010 30 (8) 1277– 1297.

    OpenUrlPubMed
12. 12.↵
    1. Ebeling C. E.

    Reliability and Maintainability Engineering. McGraw-Hill: New York, 1997.
13. 13.↵
    ICH Harmonised Tripartite Guideline, Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: chemical substances—Q6A, Current Step 4, version dated 6 October 1999, retrieved September 29, 2011, from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6A/Step4/Q6Astep4.pdf.
14. 14.↵
    1. Kolaczkowski A,
    2. Forester J,
    3. Lois E.,
    4. Cooper S.

    Good Practices for Implementing Human Reliability Analysis (HRA) Final Report, U.S. Nuclear Regulatory Commission, April 2005, http://pbadupws.nrc.gov/docs/ML0511/ML051160213.pdf, accessed April 6, 2012.
15. 15.↵
    1. Thornton A. C.

    Variation Risk Management; John Wiley & Sons: Hobokenn NJ, 2004.
16. 16.↵
    1. Meeker W. Q.,
    2. Escobar L. A.

    Statistical Methods for Reliability Data; John Wiley & Sons: Hoboken, NJ, 1998.
17. 17.↵
    1. Peterson J. J.

    A Bayesian approach to the ICH Q8 definition of design space. J. Biopharm. Stat. 2008, 18 (5), 959–975.

    OpenUrlPubMed
18. 18.↵
    1. Claycamp H. G.

    Risk, uncertainty, and process analytical technology. J. Process Anal. Technol. 2006, 3 (2), 8–12.

    OpenUrl